Suven Life Surges On Getting Patent For Neuro Degenerative Drug

New Delhi: Shares of Suven Life Sciences rose over 5 per cent today as the company has been granted one product patent each by Europe and Israel for a drug used in the treatment of neuro-degenerative diseases. 

The stock gained 5.22 per cent to Rs 204.30 on BSE. 

At NSE, shares of the company went up 5.27 per cent to Rs 204.50. 

The company has been granted "one product patent from Europe and one product patent from Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases," it said in a BSE filing today. 

The patents are valid through 2030 and 2029 respectively, the company added. 

With these new patents, Suven has a total of 23 patent from Europe and 12 from Israel.

New Delhi: Shares of Suven Life Sciences rose over 5 per cent today as the company has been granted one product patent each by Europe and Israel for a drug used in the treatment of neuro-degenerative diseases. 

The stock gained 5.22 per cent to Rs 204.30 on BSE. 

At NSE, shares of the company went up 5.27 per cent to Rs 204.50. 

The company has been granted "one product patent from Europe and one product patent from Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases," it said in a BSE filing today. 

The patents are valid through 2030 and 2029 respectively, the company added. 

With these new patents, Suven has a total of 23 patent from Europe and 12 from Israel.

New Delhi: Shares of Suven Life Sciences rose over 5 per cent today as the company has been granted one product patent each by Europe and Israel for a drug used in the treatment of neuro-degenerative diseases. 

The stock gained 5.22 per cent to Rs 204.30 on BSE. 

At NSE, shares of the company went up 5.27 per cent to Rs 204.50. 

The company has been granted "one product patent from Europe and one product patent from Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases," it said in a BSE filing today. 

The patents are valid through 2030 and 2029 respectively, the company added. 

With these new patents, Suven has a total of 23 patent from Europe and 12 from Israel.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

lock-gif
Register for Free
to continue reading
Sign Up with Google
OR
Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit. Feel free to Add NDTV Profit as trusted source on Google.
GET REGULAR UPDATES
Add us to your Preferences
Set as your preferred source on Google